• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOMET FRANCE S.A.R.L. OPTIPAC 60 REFOBACIN PLUS BONE CEMENT; BONE CEMENT, ANTIBIOTICS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOMET FRANCE S.A.R.L. OPTIPAC 60 REFOBACIN PLUS BONE CEMENT; BONE CEMENT, ANTIBIOTICS Back to Search Results
Catalog Number 4721502084-3
Device Problem Improper Chemical Reaction (2952)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 07/20/2020
Event Type  malfunction  
Manufacturer Narrative
(b)(4).Foreign report source: (b)(6).The device will not be returned to the manufacturer.Therefore it will not be analyzed.The device manufacturing quality record indicates that the released product met all requirements to perform as intended.The investigation is in progress.Once the investigation has been completed, a follow-up mdr will be submitted.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.
 
Event Description
It was reported that the cement hardened too quickly (after about 5 min).No adverse event has been reported has the result of this malfunction.
 
Event Description
It was reported that the cement hardened too quickly (after about 5 min).No adverse event has been reported has the result of this malfunction.
 
Manufacturer Narrative
(b)(4).The product analysis can't be performed as the product was not returned.A retain sample of batch a927a02665 has been tested in the laboratory under standardized conditions (23°c; rel.Humid >=40 %).No unusual behavior during mixing, handling or setting.The reported behavior of the cement cannot be reproduced.The device manufacturing quality record indicate that the released product met all requirements to perform as intended.A complaint extract was done regarding cement paste too short setting time: - 4 complaints (7 products), this one included, have been recorded on optipac 60 refobacin plus bone cement-3, reference (b)(4) -3, from (b)(6) 2020.- 2 complaints (4 products), this one included, have been recorded on optipac 60 refobacin plus bone cement-3, reference (b)(4) -3, batch a927a02665.According to available data, root cause of the event was unable to be determined.However, there is no evidence that the event is related to the product.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.Zimmer biomet will continue to monitor for trends.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTIPAC 60 REFOBACIN PLUS BONE CEMENT
Type of Device
BONE CEMENT, ANTIBIOTICS
Manufacturer (Section D)
BIOMET FRANCE S.A.R.L.
plateau de lautagne bp75
valence cedex 26903
FR  26903
MDR Report Key10336702
MDR Text Key202011240
Report Number3006946279-2020-00139
Device Sequence Number1
Product Code MBB
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 11/25/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/29/2020
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/31/2021
Device Catalogue Number4721502084-3
Device Lot NumberA927A02665
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Date Manufacturer Received11/19/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-